Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Systemic Idiopathic Juvenile Arthritis - Overview Systemic Idiopathic Juvenile Arthritis - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Systemic Idiopathic Juvenile Arthritis - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Systemic Idiopathic Juvenile Arthritis - Companies Involved in Therapeutics Development Alteogen Inc Johnson & Johnson Livzon Pharmaceutical Group Inc Mycenax Biotech Inc Novartis AG Oncobiologics Inc Systemic Idiopathic Juvenile Arthritis - Drug Profiles adalimumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress adalimumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress adalimumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress canakinumab - Drug Profile Product Description Mechanism Of Action R&D Progress golimumab - Drug Profile Product Description Mechanism Of Action R&D Progress tocilizumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress tocilizumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress tocilizumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress Systemic Idiopathic Juvenile Arthritis - Dormant Projects Systemic Idiopathic Juvenile Arthritis - Discontinued Products Systemic Idiopathic Juvenile Arthritis - Product Development Milestones Featured News & Press Releases Sep 03, 2013: Novartis receives EU approval for Ilaris in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis Jul 25, 2013: CHMP Adopts Positive Opinion For Novartis's Ilaris May 10, 2013: Novartis's Ilaris Receives Approval From FDA For Treatment Of Active Systemic Juvenile Idiopathic Arthritis Dec 19, 2012: Novartis's ACZ885 Significantly Relieves Symptoms In Patients With Serious Form Of Childhood Arthritis In Phase III Trials Jun 06, 2012: Novartis Announces New Data From Two Trials Of ACZ885 At Annual Congress Of EULAR 2012 Nov 16, 2011: Novartis Study Shows ACZ885 Provides Substantial Symptom Relief In 84% Of Patients With Most Serious Form Of Childhood Arthritis Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development for Systemic Idiopathic Juvenile Arthritis, H1 2018 Number of Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 Number of Products by Stage and Target, H1 2018 Number of Products by Stage and Mechanism of Action, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Systemic Idiopathic Juvenile Arthritis - Pipeline by Alteogen Inc, H1 2018 Systemic Idiopathic Juvenile Arthritis - Pipeline by Johnson & Johnson, H1 2018 Systemic Idiopathic Juvenile Arthritis - Pipeline by Livzon Pharmaceutical Group Inc, H1 2018 Systemic Idiopathic Juvenile Arthritis - Pipeline by Mycenax Biotech Inc, H1 2018 Systemic Idiopathic Juvenile Arthritis - Pipeline by Novartis AG, H1 2018 Systemic Idiopathic Juvenile Arthritis - Pipeline by Oncobiologics Inc, H1 2018 Systemic Idiopathic Juvenile Arthritis - Dormant Projects, H1 2018 Systemic Idiopathic Juvenile Arthritis - Discontinued Products, H1 2018List of Figures Number of Products under Development for Systemic Idiopathic Juvenile Arthritis, H1 2018 Number of Products under Development by Companies, H1 2018 Number of Products by Targets, H1 2018 Number of Products by Stage and Targets, H1 2018 Number of Products by Mechanism of Actions, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Stage and Molecule Types, H1 2018